Oncology - Breast Cancer | |
|---|---|
| Study Name | Principal Investigator |
| EA1181 (CompassHER2-pCR) – A de-escalation study assessing the effect of decreasing chemotherapy in patients with HER2 positive breast cancer, with no evidence of cancer remaining after pre-operative chemotherapy and HER2-targeted therapy. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Yadyra Rivera, MD |
| A011202 – A study evaluating the role of Axillary (Armpit) Lymph Node Removal in Breast Cancer Patients with Positive Sentinel Lymph Nodes after Preoperative Chemotherapy. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Yadyra Rivera, MD |
| NRG-BR004 – A study of Paclitaxel/Trastuzumab/Pertuzumab with Immunotherapy (Atezolizumab) or Placebo as Initial therapy for HER2 Positive Metastatic Breast Cancer. Read more. |
Yadyra Rivera, MD |
| EAZ171 – A Study of Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients with Stage I-III Breast Cancer. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Yadyra Rivera, MD |
| A191901 GETSET Study – An Additional Support Program Via Text Messaging and Telephone-Based Counselling for Breast Cancer Patients Receiving Hormonal Therapy. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Yadyra Rivera, MD |
| S1501 – Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Yadyra Rivera, MD |
| NRG-BR007 – A De-Escalation of Breast Radiation Trial for Hormone Sensitive, Her2 Negative, Oncotype Recurrence Score less than or equal 18 Breast cancer. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Raimonda Goldman, MD |
Oncology - Colorectal Cancer | |
| Study Name | Principal Investigator |
| A221805 – A Study of Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in patients with Stage II-III Colorectal Cancer. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Jason Lee, MD |
Oncology - Pancreatic Cancer | |
| Study Name | Principal Investigator |
| EA2186 – A Study Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan For Older Patients With Pancreatic Cancer That Has Spread. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Jason Lee, MD |
Oncology - Prostate Cancer | |
| Study Name | Principal Investigator |
| S1802 – A Study of Standard Systemic Therapy with or Without Definitive Treatment in Treating Patients with Metastatic Prostate Cancer. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Jason Lee, MD |
